Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: A randomized comparative trial

Pediatric Infectious Disease Journal

Volumn 29, Issue 11, 2010, Pages

  Snape, Matthew D ^a   Dawson, Tom ^a   Oster, Philipp ^b   Evans, Anita ^a   John, Tessa M ^a   Ohene Kena, Brigitte ^a   Findlow, Jamie ^c   Yu, Ly Mee ^a   Borrow, Ray ^c   Ypma, Ellen ^d   Toneatto, Daniela ^b   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Novartis Vaccines and Diagnostics   (Netherlands)

Author keywords

meningococcal serogroup B vaccine infants

Indexed keywords

BACTERIUM ANTIBODY; COMPLEMENT; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESION A; NEISSERIAL HEPARIN BINDING ANTIGEN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE VESICLE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 77957941966     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f59f6d     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention (CDC). Revised recommendations of the advisory committee on immunization practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2007;56:794-795.
2. Snape MD, Perrett KP, Ford K, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants. JAMA. 2008;299:173-184.
3. European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe 2006. London: Health Protection Agency; 2006. Available at: www.euibis.org.
4. Centers for Disease Control and Prevention. Active bacterial core surveillance reports, Emerging Infections Program Network, Neissaria meningitidis. 2006. Available at: http://www.cdc.gov/ncidod/dbmd/abcs/ survreports/mening06.pdf. Accessed October 28, 2008.
5. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138:4402-4407.
6. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195-207.
7. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-1096.
8. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166:817-823.
9. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis. 2010;10:112-124.
10. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816-1820.
11. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19:2688-2691.
12. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103:10834-10839.
13. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789-799.
14. Bambini S, Muzzi A, Olcen P, et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine. 2009;27:2794-2803.
15. Welsch JA, Ram S, Koeberling O, et al. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis. 2008;197:1053-1061.
16. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177:501-510.
17. Beernink PT, Welsch JA, Harrison LH, et al. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis. 2007;195:1472-1479.
18. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379-389.
19. Jacobsson S, Hedberg ST, Molling P, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine. 2009;27:1579-1584.
20. Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol. 2010;17:919-929.
21. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088-2100.
22. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA. 2010;107:3770-3775.
23. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55:687-698.
24. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195:1445-1454.
25. Comanducci M, Bambini S, Caugant DA, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun. 2004;72:4217-4223.
26. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28:5023-5030.
27. Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis. 2008;198:262-270.
28. Plested JS, Welsch JA, Granoff DM. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol. 2009;16:785-791.
29. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-5107.
30. Oster P, O'Hallahan J, Aaberge I, et al. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25:3075-3079.
31. Miller E, Pollard AJ, Borrow R, et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Paper presented at: European Society of Paediatric Infectious Disease; May 13-17, 2008; Graz, Austria.
32. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27:3417-3421.
33. Welsch JA, Moe GR, Rossi R, et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis. 2003;188:1730-1740.
34. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J. 2007;26:345-350.
35. Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules. Available at: http://clinicaltrials.gov/ct2/show/NCT00721396?term=meningococcal&lead= novartis&cntry1=EU%3AGB&rank=8. Accessed February 10, 2010.
36. Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants. Available at: http://clinicaltrials.gov/ct2/show/NCT00937521?recr=Open&intr=vaccine& lead=novartis&rank=1. Accessed February 10, 2010.
37. Su EL, Snape MD, Dawson T, et al. Bactericidal activity against an extended panel of meningococcal strains following immunisation with novel serogroup B meningococal vaccines in infancy. Paper presented at: European Society of Paediatric Infectious Diseases; June 9-13, 2009; Brussels, Belgium.
38. Neisseria.org. Available at: http://neisseria.org/. Accessed June 16, 2009.